Compare · DERM vs VRCA
DERM vs VRCA
Side-by-side comparison of Journey Medical Corporation (DERM) and Verrica Pharmaceuticals Inc. (VRCA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DERM and VRCA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- DERM is the larger of the two at $104.2M, about 2.1x VRCA ($49.1M).
- VRCA has been more active in the news (7 items in the past 4 weeks vs 4 for DERM).
- VRCA has more recent analyst coverage (13 ratings vs 7 for DERM).
- Company
- Journey Medical Corporation
- Verrica Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $104.2M
- $49.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2018
- News (4w)
- 4
- 7
- Recent ratings
- 7
- 13
Journey Medical Corporation
Journey Medical Corporation develops and commercializes pharmaceutical products for the treatment of dermatological conditions. It markets generic prescription drugs for dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; which has completed phase II clinical trial for treating common warts; and that is in phase II clinical trial for the treatment of external genital warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Latest DERM
- SEC Form 10-Q filed by Journey Medical Corporation
- Journey Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
- Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Journey Medical Corporation
- Journey Medical Corporation to Participate in September 2026 Investor Conferences
- Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
- SEC Form 10-Q filed by Journey Medical Corporation
- Journey Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Latest VRCA
- SEC Form SCHEDULE 13G filed by Verrica Pharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Verrica Pharmaceuticals Inc.
- SEC Form 10-Q filed by Verrica Pharmaceuticals Inc.
- Verrica Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results
- Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
- Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
- Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
- Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
- Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences